在小鼠中,BC-1通过调节B细胞的IgD和BCR-NF-κB信号通路来改善原诱导的关节炎
LiHua Mu1, Hong Yin1, Rui Jing1
1Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, Beijing 100853, China.
International immunopharmacology
|July 17, 2025
概括
贝西亚calthaefolia saponin BC-1 通过减少炎症和骨损伤,有效治疗类风湿性关节炎. 它通过抑制B细胞中的IgD和BCR-NF-κB通路而起作用,提供了一种新的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 传统中国医药 传统中国医药
背景情况:
- 类风湿性关节炎 (RA) 是一种衰弱的自身免疫性疾病,有效治疗方法有限.
- 在TCM中使用的Beesia calthaefolia含有已知的抗炎性质的沙宁BC-1.
- BC-1的精确抗RA机制在很大程度上仍未被描述.
研究的目的:
- 阐明BC-1的特定抗风湿性关节炎机制.
- 在原诱导关节炎 (CIA) 鼠标模型中评估BC-1的治疗潜力.
主要方法:
- 在DBA1小鼠中建立了原诱导关节炎 (CIA) 模型.
- 通过飞行时间的细胞计 (CyTOF) 分析脏免疫细胞.
- 评估关节炎的严重程度,关节损伤,以及血清炎症标志物 (TNF-α,IL-1β,IL-6,PGE2,COX-2).
主要成果:
- 在CIA小鼠中,BC-1显著减轻了关节炎的严重程度,并减少了关节炎症,软骨和骨损伤.
- BC-1降低了TNF-α,IL-1β,IL-6,PGE2和COX-2的血清水平升高.
- BC-1 正常化了增加的B细胞群和IgD水平,并抑制了B细胞中的BCR-NF-κB信号通路.
结论:
- BC-1在类风湿性关节炎治疗中显示出显著的治疗潜力.
- 该机制涉及抑制IgD表达和B细胞中的BCR-NF-κB信号通路.
- BC-1代表了一种来自中国传统医学的有前途的新药,用于治疗RA.
相关概念视频
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K


